Market revenue in 2023 | USD 3,117.7 million |
Market revenue in 2030 | USD 5,294.2 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Immunohistochemistry |
Fastest growing segment | Digital Pathology and Workflow |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunohistochemistry, In situ Hybridization, Primary & Special Staining, Digital Pathology and Workflow, Anatomic Pathology, Molecular Pathology |
Key market players worldwide | Roche Holding AG ADR, Abbott Laboratories, Thermo Fisher Scientific Inc, Siemens AG, Danaher Corp, BioMerieux SA, Qiagen NV, BD, Merck KGaA, GE Aerospace, Agilent Technologies Inc, Biogenex, Cell Signaling Technology, Bio SB, DiaGenic |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to tissue diagnostics market will help companies and investors design strategic landscapes.
Immunohistochemistry was the largest segment with a revenue share of 25.7% in 2024. Horizon Databook has segmented the U.S. tissue diagnostics market based on immunohistochemistry, in situ hybridization, primary & special staining, digital pathology and workflow, anatomic pathology, molecular pathology covering the revenue growth of each sub-segment from 2018 to 2030.
According to National Cancer Institute, estimated new cancer cases in 2021 in the U.S. is 1.9 million. Ongoing strategic investments on cancer research have made the U.S. a global leader in the field. Recently, U.S. FDA approved Keytruda (pembrolizumab) for tumors with specific genetic changes, regardless of the type.
Keytruda has already been approved for lung cancer, Hodgkin lymphoma, and other cancer types. Cancer Prevention and Control Research Network is a flagship program by CDC for preventing cancer. Through colorectal cancer prevention and control initiatives, CDC is conducting and promoting initiatives for screening for colorectal cancer.
Molecular testing guidelines released by College of American Pathologist, the International Association for the Study of Lung Cancer, and Association of Molecular Pathology recommend that the test results be available within 2 weeks (10 working days) from the time the lab receives a specimen.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. tissue diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. tissue diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account